HK$2.65-HK$0.05 (-1.85%)
Jilin Province Huinan Changlong Bio-pharmacy Company Limited’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
Loading market information…
HKSE · 2500.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Venus Medtech (Hangzhou) Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Venus Medtech (Hangzhou) Inc.’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Venus Medtech (Hangzhou) Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 |
|---|
| Jun 28, 2024 |
| -HK$0.89-37.68% vs estimate |
| HK$260.94M-8.69% vs estimate |
| Q2 2023 | Aug 31, 2023 | -HK$0.86-19.44% vs estimate | HK$276.42M+1.13% vs estimate |
|---|
| Q4 2022 | Mar 31, 2023 | -HK$2.23-514.58% vs estimate | HK$223.79M-10.22% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$2.65-HK$0.05 (-1.85%)
Jilin Province Huinan Changlong Bio-pharmacy Company Limited’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
HK$1.83+HK$0.08 (+4.57%)
Arrail Group Limited’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
HK$9.18+HK$0.21 (+2.28%)
Beijing Airdoc Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.63% below the high.
HK$0.90HK$0.00 (0.0%)
Kindstar Globalgene Technology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.19% below the high.
HK$0.98+HK$0.01 (+1.03%)
Brii Biosciences Limited’s quoted price sits in the lower half of its reported 52-week range, 48.42% below the high.
HK$3.80HK$0.00 (0.0%)
Wuhan YZY Biopharma Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 54.76% below the high.
HK$4.08+HK$0.18 (+4.62%)
Gaush Meditech Ltd’s quoted price sits in the lower half of its reported 52-week range, 59.16% below the high.
HK$4.13HK$0.00 (0.0%)
Sirnaomics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.47% below the high.
